Real-life safety and effectiveness of amlodipine/valsartan combination in the treatment of hypertension

Advances in Therapy

Volumn 28, Issue 2, 2011, Pages 134-149

  Chazova, Irina E ^a   Dongre, Neelesh ^b   Vigdorchik, Alexey V ^c  

^a Russian Cardiology Scientific Industrial Complex ^*  (Russian Federation)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Novartis Pharma LLC   (Russian Federation)

Author keywords

amlodipine; combinat ion hypertension; valsartan

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE PLUS VALSARTAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORAL ANTIDIABETIC AGENT;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE GASTROENTERITIS; ADULT; AGED; ANXIETY; ARTICLE; BANGLADESH; BLOOD PRESSURE REGULATION; CHILL; CHINA; COUGHING; DIABETES MELLITUS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSLIPIDEMIA; EDEMA; EGYPT; EPIGASTRIC PAIN; FATIGUE; FEMALE; FEVER; FLUSHING; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; HYPERTENSION; IMPOTENCE; INSOMNIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; OPEN STUDY; PAKISTAN; PARESTHESIA; PNEUMONIA; RECOMMENDED DRUG DOSE; RHINITIS; RHINOPHARYNGITIS; RUSSIAN FEDERATION; SIDE EFFECT; SUBDURAL HEMATOMA; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; VOMITING;

ADMINISTRATION, ORAL; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BANGLADESH; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CHINA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG SYNERGISM; EGYPT; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALAYSIA; MALE; MIDDLE AGED; PAKISTAN; PRODUCT SURVEILLANCE, POSTMARKETING; RUSSIA; SEVERITY OF ILLNESS INDEX; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 79952533426     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-010-0099-1     Document Type: Article

References (18)

1. G. Mancia S. Laurent E. Agabiti-Rosei, et al. 2009 Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document J Hypertens 27 2121 2158 19838131 10.1097/HJH.0b013e328333146d 1:CAS:528:DC%2BD1MXhsVCjs7bM
2. K. Wolf-Maier R.S. Cooper J.R. Banegas, et al. 2003 Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States JAMA 289 2363 2369 12746359 10.1001/jama.289.18.2363 (Pubitemid 37430168)
3. C. Lawes S. Vander Hoorn A. Rodgers 2008 Global burden of blood-pressure-related disease, 2001 Lancet 371 1513 1518 18456100 10.1016/S0140-6736(08)60655-8 (Pubitemid 351626187)
4. S. Lewington R. Clarke N. Qizilbash R. Peto R. Collins Prospective Studies Collaboration 2002 Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 1903 1913 12493255 10.1016/S0140-6736(02) 11911-8 (Pubitemid 35472129)
5. K. Wolf-Maier R.S. Cooper H. Kramer, et al. 2004 Hypertension treatment and control in five European countries, Canada, and the United States Hypertension 43 10 17 14638619 10.1161/01.HYP.0000103630.72812.10 1:CAS:528:DC%2BD3sXpvVeqtr8%3D (Pubitemid 38031904)
6. S.A. Shalnova Y.A. Balanova V.V. Konstantinov, et al. 2006 Arterial hypertension: prevalence, patients' awareness, treatment patterns and efficacy among Russian Federation population Russian Cardiology Journal 4 45 51
7. S.A. Shalnova A.A. Deev R.G. Oganov 2006 Monitoring arterial hypertension in Russia Circulation 113 f83 84 16739262
8. Directive 2001/20/EC of the European parliament and of the council of 4 April on the approximatio of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Communities. 2001;121:34-44.
9. T. Philipp T.R. Smith R. Glazer, et al. 2007 Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension Clin Ther 29 563 580 17617280 10.1016/j.clinthera.2007.03.018 1:CAS:528: DC%2BD2sXmvVWnurs%3D (Pubitemid 47028551)
10. T.R. Smith T. Philipp B. Vaisse, et al. 2007 Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies J Clin Hypertens (Greenwich) 9 355 364 10.1111/j.1524-6175.2007.06689.x 1:CAS:528:DC%2BD2sXmtFKnt7k%3D
11. D. Poldermans R. Glazes S. Kargiannis, et al. 2007 Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension Clin Ther 29 279 289 17472820 10.1016/j.clinthera.2007.02.003 1:CAS:528:DC%2BD2sXks1Gltbk%3D (Pubitemid 46661857)
12. Y. Allemann B. Fraile M. Lambert M. Barbier F. Ferber J. Izzo 2008 A randomized, double-blind, multicenter study to evaluate the efficacy of the combination of amlodipine and valsartan in hypertensive patients uncontrolled on previous monotherapy: the EX-FAST Study J Clin Hypertens 10 185 194 10.1111/j.1751-7176.2008.07516.x 1:CAS:528:DC%2BD1cXksFSltr4%3D
13. P. Trenkwalder R. Schaetzl E. Borbas R. Handrock S. Klebs 2008 Combination of amlodipine 10 mg and valsartan 160 mg lowers blood pressure in patients with hypertension not controlled by an ACE inhibitor/CCB combination Blood Pressure 17 suppl.2 13 21 20973652 10.1080/08038020802488855
14. N. Braun H.-J. Ulmerb A. Ansaric R. Handrock S. Klebs 2009 Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination Curr Med Res Opin 25 421 430 19192987 10.1185/03007990802656468 1:CAS:528:DC%2BD1MXltVWms7s%3D
15. F.H. Messerli 2002 Vasodilatory edema: a common side effect of antihypertensive therapy Curr Cardiol Rep. 4 479 482 12379167 10.1007/s11886-002-0110-9
16. K. Jamerson O. Nwose L. Jean-Louis L. Schofield D. Purkayastha M. Baron 2004 Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension Am J Hypertens 17 495 501 15177521 10.1016/j.amjhyper.2004.02.003 1:CAS:528:DC%2BD2cXks1Wlurw%3D (Pubitemid 38726163)
17. J. Schrader A. Salvetti C. Calvo, et al. 2009 The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg Int J Clin Pract 63 217 225 19196360 10.1111/j.1742-1241.2008.01977.x 1:CAS:528:DC%2BC3cXksVKmsrs%3D
18. R. Fogari A. Zoppi G. Derosa, et al. 2007 Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients J Hum Hypertens 21 220 224 17215848 1:CAS:528:DC%2BD2sXhslWgsLY%3D